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iabetes and
rug-Eluting Stents
hat You Get and What You Don’t*
teven P. Marso, MD
ansas City, Missouri
he clinical introduction of drug-eluting stents (DES) in
003 was a major milestone in the field of interventional
ardiology. There was an early and rapid adoption of DES
nto clinical practice, which has undoubtedly impacted our
nterventional practices. In particular, DES use has
rompted operators to intervene in many more patients with
dvanced disease, often with accompanying comorbidities.
n the past, these patients were likely referred for coronary
rtery bypass grafting (CABG) or treated conservatively.
erhaps no comorbidity has received more attention in the
ercutaneous coronary intervention (PCI) population than
iabetes mellitus. Patients with diabetes have long been
ecognized as a complex PCI cohort. These observations
ate back to even the initial National Heart, Lung, and
lood Institute percutaneous transluminal coronary angio-
lasty registry publications (1). Today, diabetes continues to
e associated with an increased risk of major adverse
ardiovascular events, including death and myocardial in-
arction (MI). Along with lesion length and reference vessel
iameter, diabetes is also consistently associated with reste-
osis and need for repeat revascularization after PCI.
See page 139
Thus, the findings from Mulukutla et al. (2) in this issue
f JACC: Cardiovascular Interventions are of interest to
racticing interventionalists. These investigators report
-year outcomes for a cohort of diabetic patients enrolled in
he National Heart, Lung, and Blood Institute Dynamic
CI Registry. In over 2,500 patients with diabetes, DES
herapy decreased the need for repeat revascularization
ompared with bare-metal stents (BMS). Although the
nsulin-treated population was somewhat underpowered,
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From Saint Luke’s Health System, Mid America Heart Institute, Kansas City,
issouri. Dr. Marso is a consultant for Amylin, Sanofi-Aventis, and Volcanor
orporation and has received research grants from Boston Scientific, The Medicines
ompany, and Volcano Corporation.he magnitude of benefit in DES-treated diabetic patients
as similar between patients receiving and not receiving
nsulin treatment. There was no apparent procedural-related
ost of death or nonfatal MI.
This work raises numerous points for discussion. Al-
hough multicenter national PCI registries provide impor-
ant insights into PCI treatment strategies and outcomes,
hanges in patient demographics and interventional tech-
iques must be considered when interpreting these findings.
s the investigators note, registry enrollment spanned
early a decade. In observational registries of extended
uration, important bias is often present in selecting treat-
ent strategies that cannot be fully accounted for with
tatistical methods. Over the past 10 years, much has
hanged with respect to the PCI population. Today, PCI
atients are older and have a greater number of comorbidi-
ies, including decreased ejection fraction, chronic renal
nsufficiency, and a greater number of diseased vessels (3)
hen compared with the PCI population 10 years ago. The
revalence of diabetes in the PCI population has increased
ramatically. At our institution, the prevalence of diabetes
n the setting of PCI increased from 8% to more than 30%
ver a 20-year time span. Changing demographics result
n very different short- and long-term risks for disease
rogression and subsequent atherosclerotic complica-
ions, including death and MI. Evaluating therapies
olely based on these observational datasets often lead to
rroneous conclusions regarding the benefit or risk of
valuable therapies.
This was especially evident during the evaluation phase of
ES. The introduction of DES has likely influenced
perator decisions regarding revascularization strategy. For
xample, data (4) over a 5-year period from the American
ollege of Cardiology National Cardiovascular Data Reg-
stry (ACC/NCDR) catheter/PCI registry show a rapid
iffusion of DES. Before 2003, approximately 1 of 4
atients with a class I indication for CABG underwent PCI.
y the end of 2004, DES were used in over 80% of all PCI
ases. In the DES era, this ratio increased to 1 of 3.
urthermore, for every 10% increase in DES use, there was
corresponding 4% increase in PCI attempts in patients
ith a class I indication for CABG. These findings suggest
willingness on the part of operators to attempt PCI more
ften in complex cases. Data from Sweden (5) further
upport the contention that the DES cohort is more
omplex. The DES-treated patients were more likely to
ave diabetes, multistent procedures, prior PCI, and prior
ABG compared with the BMS cohort. It is likely that
hanging demographics between DES and BMS cohorts
artially explain the studies presented in late 2006 showing
n increased hazard for death/MI. For example, early
tudies suggested an increase in the risk of mortality for
ES-treated patients (6,7). In a large meta-analysis of 17
andomized trials comparing sirolimus-eluting or paclitaxel-
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Editorial Comment
149luting stents to BMS, Nordmann et al. (6) found a graded
ncrease in all-cause mortality associated with DES with
ncreasing length of follow-up. However, several recent
ublications have improved clarity (and reversed thought)
bout the safety of DES (8 –12). For example, in a meta-
nalysis of 38 randomized trials, Stettler et al. (9) reported
ignificantly lower target lesion revascularization rates in
atients randomized to sirolimus-eluting or paclitaxel-
luting stents compared with BMS but no differences in
eath or MI between either DES platform or BMS.
Likewise, there has also been increasing confusion with
espect to the risk or benefit of DES in diabetic patients
ased on early published data. For this reason alone,
ulukutla et al. (2) provide an important contribution to
he literature by helping to clarify the risk/benefit of DES in
he diabetic population. Early sirolimus data (13,14) showed
n impressive reduction in late loss and target vessel revas-
ularization (TVR), yet the benefit seemed to be attenuated
n the insulin-treated diabetic subgroup. However, as the
tudies accumulated and pooled analysis became available,
oyden et al. (15) showed an acceptable mean late loss of
.12 mm in diabetic patients randomized to sirolimus-
luting stents. Paclitaxel-eluting stents seem to have less
ariability in the late loss in diabetic patients, albeit numer-
cally greater (0.34 mm) (15) when compared with
irolimus-eluting stents. Other data have raised concerns
bout the safety of sirolimus-eluting stents in the diabetic
ohort. Spaulding et al. (8) compared 4 sirolimus trials that
howed a significant increase in risk of death for sirolimus-
reated diabetic patients when compared with BMS (overall
urvival 87.8% vs 95.6%; sirolimus-eluting stents vs. BMS,
  0.004). However, this finding requires cautious inter-
retation because of the very low number of events in the
iabetic subgroup. This analysis from the Dynamic Registry
f DES in diabetic patients extends findings of an early
eta-analysis (15), which clearly showed a significant re-
uction in the vessel patency for diabetic patents random-
zed to DES.
Although there is much yet to learn, there is an accumu-
ating body of literature supporting the benefit of DES in
iabetic patients. These data allow for some generalizations.
hat you get: 1) Improved vessel patency. DES improves
essel patency as measured by either late loss or need for
arget vessel revascularization. 2) An acceptable safety pro-
le. The latest studies more firmly establish DES as not
nly efficacious, but also safe. There does not seem to be an
ncreased hazard for either death or MI among diabetic
atients related to DES treatment. What you do not get: 1)
eutralization of restenosis risk. Although the data are less
han complete, it seems that diabetes will still be consis-
ently associated with the need for greater repeat revascu-
arization rates (compared with nondiabetic subjects) of the
arget lesion in the DES era. 2) An optimal DES platform
deally suited for diabetic patients. There have been a seriesf comparative studies between sirolimus and paclitaxel in
iabetic subjects. The details are beyond the scope of this
ditorial. In brief, these studies are consistently discordant.
either is definitively superior. The ideal stent has yet to be
eveloped for this high-risk group of patients. Perhaps the
hird-generation DES will provide superior efficacy for
atients with diabetes mellitus.
eprint requests and correspondence: Dr. Steven P. Marso,
aint Luke’s Health System, Mid America Heart Institute, 4401
ornall Road, Kansas City, Missouri 64111. E-mail: smarso@
aint-lukes.org.
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